Malignant neoplasm of brain
Chapter 2:Neoplasms
ICD-10 C71 is a billable code used to indicate a diagnosis of malignant neoplasm of brain.
C71 refers to malignant neoplasms of the brain, which encompass a variety of primary brain tumors that arise from the central nervous system (CNS) tissues. These tumors can be classified into several histological types, including gliomas, meningiomas, and medulloblastomas, among others. The clinical presentation of brain tumors can vary widely, depending on their location, size, and growth rate. Common symptoms include headaches, seizures, cognitive changes, and focal neurological deficits. Imaging studies, particularly MRI and CT scans, are essential for diagnosis, providing detailed visualization of the tumor's size, location, and effect on surrounding brain structures. Molecular markers, such as IDH mutations and 1p/19q co-deletion status, play a crucial role in the classification and prognosis of certain brain tumors, particularly gliomas. Accurate coding of C71 requires comprehensive documentation of the tumor type, location, and any relevant imaging or molecular findings, as these factors significantly influence treatment decisions and patient outcomes.
Detailed pathology reports, imaging studies, and treatment plans.
Diagnosis and management of primary brain tumors, treatment planning, and follow-up care.
Ensure accurate coding of tumor type and stage, as treatment options vary significantly.
Neurological assessments, imaging results, and symptomatology.
Evaluation of neurological deficits, seizure management, and coordination of care with oncologists.
Document neurological function changes meticulously to support coding and treatment decisions.
Used when a patient undergoes surgical intervention for a malignant brain tumor.
Operative reports detailing the procedure and findings.
Ensure coordination between neurosurgery and oncology for comprehensive care.
C71 encompasses various malignant brain tumors, including gliomas, meningiomas, and medulloblastomas, among others.
Molecular markers provide critical information for tumor classification and prognosis, which should be documented to support accurate coding.
